These studies assess whether the target animal species will willingly consume the product — covering taste, texture, smell, and ease of administration. Animals are typically offered the product under controlled conditions, and uptake rates, consumption behaviour, and any signs of aversion are recorded. From a regulatory standpoint, the output is data that supports labelling claims around palatability (e.g., "readily accepted by dogs") and can inform dosing compliance assumptions in efficacy and safety submissions.

Before committing to full GLP-compliant safety studies, pilot studies are run in a small number of target animals to get an early read on whether the product is broadly safe at anticipated therapeutic and exaggerated doses. These are exploratory by nature — looking at clinical signs, bodyweight, food consumption, and sometimes basic clinical pathology. The regulatory value is not in generating definitive safety conclusions, but in de-risking the development programme, refining dose selection, and identifying any red flags before larger investments are made.

Pharmacokinetic studies characterise how the drug is absorbed, distributed, metabolised, and excreted in the target species, while dose-ranging work identifies the exposure levels needed to achieve a therapeutic effect. These studies are typically run outside of GLP as they are hypothesis-generating rather than definitive. The output feeds directly into dose selection for pivotal studies and helps build the pharmacokinetic/pharmacodynamic (PK/PD) rationale that regulators expect to see underpinning your proposed dose regimen in the dossier.

Field studies evaluate product performance under true-to-life conditions — naturally infected or affected animals, in real clinical settings, managed by practising veterinarians. Unlike controlled laboratory efficacy studies, these capture the variability of real-world use, including different breeds, ages, concurrent conditions, and owner compliance. Regulatorily, field efficacy data is often a core component of the pivotal efficacy package required for marketing authorisation, and in some frameworks can also support post-authorisation commitments or label expansions with real-world evidence.